Margaret M. van Gilse
Corporate Officer/Principal en Bexion Pharmaceuticals, Inc. .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Ray Takigiku | M | - |
Bexion Pharmaceuticals, Inc.
 Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | 18 años |
| Scott R. Shively | M | 67 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
| Olivia Kirtley | F | 74 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | 3 años |
| Raymond Tesi | M | 68 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | 4 años |
| Cameron Durrant | M | 63 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
| Timothy Schroeder | M | 66 |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
| Jim Beach | M | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
| Catherine Pearce | F | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | 1 años |
| Chuck Scheper | M | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
| Keith A Carlson | M | - |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 10 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Margaret M. van Gilse
- Red Personal
